Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Clinicaltrials.gov ID
NCT04956640
Status
Recruiting
Study Type
Interventional, Phase 1
Sponsor
Eli Lilly and Company
Start Date
19 juillet 2021
Anticipated End Date
30 septembre 2025
Study Contact
About the Study
The purpose of this study is to find out whether the study drug, LY3537982, is safe and effective in cancer patients who have a specific genetic mutation (KRAS G12C). Patients must have already received or were not able to tolerate the standard of care, except for specific groups who have not had cancer treatment. The study will last up to approximately 4 years.
Conditions
Carcinoma, Non-Small-Cell Lung
Colorectal Neoplams
Endometrial Neoplasms
Ovarian Neoplasms
Pancreatic Neoplasms
Biliary Tract Neoplasms
Inclusion/Exclusion Criteria?
Primary, Secondary, Other Outcome Measures??
Locations in Canada
Cross Cancer Institute, Edmonton, Alberta, T6G 1Z2, Canada
Princess Margaret Hospital, Toronto, Ontario, M5G 2M9, Canada
About the Study
The purpose of this study is to find out whether the study drug, LY3537982, is safe and effective in cancer patients who have a specific genetic mutation (KRAS G12C). Patients must have already received or were not able to tolerate the standard of care, except for specific groups who have not had cancer treatment. The study will last up to approximately 4 years.
Conditions
Carcinoma, Non-Small-Cell Lung
Colorectal Neoplams
Endometrial Neoplasms
Ovarian Neoplasms
Pancreatic Neoplasms
Biliary Tract Neoplasms
Interventions
DRUG:
LY3537982
Abemaciclib
Pembrolizumab
LY3295668
Cetuximab
Pemetrexed
Cisplatin
Carboplatin
Locations in Canada
Cross Cancer Institute, Edmonton, Alberta, T6G 1Z2, Canada
Princess Margaret Hospital, Toronto, Ontario, M5G 2M9, Canada